Claris Lifesciences to Sell U.S. Injectables Division

Aug 10, 2016

Bloomberg

Indian drug maker Claris Lifesciences Ltd. has initiated the sale of its U.S. injectable-drug business, which could be worth at least $500 million, according to a Bloomberg article.

Claris is said to have asked for bids from large U.S. companies such as Baxter International by the end of August, according to sources. The sale could also draw interest from Indian companies such as Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd. and Torrent Pharmaceuticals Ltd., the article said.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments